



## Topical and Intralesional Immunotherapy for Skin Cancer

Guest Editor:

### Dr. Ángeles Flórez

1. Department of Dermatology,  
Pontevedra University Hospital,  
Pontevedra, Spain

2. DIPO Research Group, Galicia  
Sur Health Research Institute (IIS  
Galicia Sur) SERGAS-UVIGO, Vigo,  
Spain

Deadline for manuscript  
submissions:

**31 July 2024**

### Message from the Guest Editor

Skin cancer is the most common form of human cancer and has an increasing annual incidence. Currently, its management and follow-up represent a challenge for patients, physicians, and health systems due to its associated morbidity, impact on health-related quality of life, costs, and death.

Immunotherapy is revolutionizing cancer management, enabling much higher disease control rates. The immune system has been long recognized as a key element involved in the pathogenesis, progression, and persistence of skin cancer. From this scenario arises the clinical relevance of skin-directed immunotherapy, an expanding therapeutic pipeline that can be administered in different modalities and combinations without inducing systemic toxicity.

In this Special Issue of *Cancers*, experts in the field will update and critically analyse the available evidence on topical and intralesional immunotherapy for skin cancer, focusing on non-melanoma skin cancer, melanoma, and primary cutaneous lymphoma. New promising approaches will also be reviewed.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)